Can-Fite BioPharma: Namodenoson Shows Liver Cancer & Protective Effects
Ticker: CANF · Form: 6-K · Filed: Jun 24, 2024 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: biotech, drug-development, press-release
TL;DR
Can-Fite's Namodenoson shows anti-cancer and protective effects in the liver, per June 24th press release.
AI Summary
On June 24, 2024, Can-Fite BioPharma Ltd. announced breakthrough findings demonstrating Namodenoson's anti-cancer and protective effects in the liver. The press release, attached as Exhibit 99.1 to this 6-K filing, details the mechanisms behind these effects.
Why It Matters
These findings could advance the development of Namodenoson as a treatment for liver cancer and related conditions, potentially impacting patient outcomes and the company's therapeutic pipeline.
Risk Assessment
Risk Level: medium — The company is a clinical-stage biopharmaceutical firm, and the success of its drug candidates like Namodenoson is subject to significant clinical and regulatory risks.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Issuer of the report and developer of Namodenoson.
- Namodenoson (drug) — Drug candidate showing anti-cancer and protective effects in the liver.
- June 24, 2024 (date) — Date of the press release announcing the findings.
FAQ
What specific anti-cancer and protective mechanisms of Namodenoson in the liver were demonstrated?
The press release, incorporated as Exhibit 99.1, details these breakthrough findings, but the specific mechanisms are not enumerated in the 6-K filing itself.
Is this press release the only document filed with the SEC today?
No, this 6-K filing includes the press release as Exhibit 99.1 and is part of a public document count of 2.
What is the filing date and period of report for this 6-K?
The filing date and the conformed period of report are both June 24, 2024.
What is Can-Fite BioPharma Ltd.'s primary business classification?
The company's Standard Industrial Classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.
Does Can-Fite BioPharma Ltd. file annual reports under Form 20-F or 40-F?
The company indicates it files annual reports under Form 20-F.
Filing Stats: 197 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-06-24 07:04:56
Filing Documents
- ea0208353-6k_canfite.htm (6-K) — 9KB
- ea020835301ex99-1_canfite.htm (EX-99.1) — 11KB
- 0001213900-24-054980.txt ( ) — 21KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 24, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 2